BRD4 and leukemia: Combination therapy with the BRD4 inhibitor ABBV-744 and the GSK3 inhibitor CHIR-98014 considerably suppresses KMT2A-rearranged leukemia progression in patient-derived xenograft models in mice, confirming ABBV-744 and CHIR-98014 combination therapy as an effective therapeutic strategy [54].